Thailand HDV Cohort

The HIV Netherlands Australia Thailand Research Collaboration3,152 enrolled

Overview

There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment

The prevalence of HDV remains ill-defined, mainly for lack of appropriate testing and screening. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. This data will inform the guideline whether HDV screening among HBV/HIV is required. This study has plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. This Nationwide survey of HDV is collaboration between Thai liver society, Thai AIDS society, Thai Red Cross AIDS research centre, Faculty of Medicine Chulalongkorn University, and AIDS TB and STI Control Division, Department of Disease control, MOPH Thailand. All findings will be shared and discussed to develop the National guideline for screening, treatment and care.

Study Type

OBSERVATIONAL

Enrollment

3,152

Conditions

HDV

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female, aged 18 years and older 2. Chronically-infected with HBV, as defined by: Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result 3. Provide signed and dated informed consent form. Exclusion Criteria: Non chronic HBV

Outcomes

Primary Outcomes

prevalence of HDV

prevalence of HDV in patients with cirrhosis

Time frame: 1 year

prevalence of HDV

prevalence of HDV in patients with non cirrhosis

Time frame: 1 year

prevalence of HDV

prevalence of HDV in HIV positive people with injecting drug use

Time frame: 1 year

prevalence of HDV

prevalence of HDV in HIV negative people with injecting drug use

Time frame: 1 year

prevalence of HDV

prevalence of HDV among HBV/HIV men who have sex with men

Time frame: 1 year

prevalence of HDV

prevalence of HDV among HBV/HIV cisgender male patients

Time frame: 1 year

prevalence of HDV

prevalence of HDV among prisoners

Time frame: 1 year